



# NEW INSIGHTS INTO ANTIBACTERIAL AND ANTITUMOR EFFECTS OF STRUCTURALLY VERSATILE AMINO ACID-BASED AND NON-PROTEINOGENIC COMPOUNDS



Martina I. Peeva<sup>1</sup>, Maya G. Georgieva<sup>1</sup>, Aneliya A. Balacheva<sup>1</sup>, Svetoslav Dimov<sup>2</sup>, Nikolay T. Tzvetkov<sup>1,\*</sup>


1) Department of Biochemical Pharmacology and Drug Design, Institute of Molecular Biology, Bulgarian Academy of Sciences, Acad. G. Bonchev str. Bl. 21, Sofia 1113, Bulgaria  
2) Faculty of Biology, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria

\*Corresponding author: [ntzvetkov@bio21.bas.bg](mailto:ntzvetkov@bio21.bas.bg) (NTT)

## Introduction


The honey bee (*Apis mellifera*) has been known to mankind since ancient times. The last few decades, honey bee populations have been declining dramatically worldwide due to various causes including pesticides, bacterial diseases and parasites [1]. That leads to a pressing problem with a huge global economic, environmental, social, and public health impact.

The American Foulbrood disease (AFB) is an infection that still belong to the most deleterious honey bee diseases (Fig. 1) [1,2]. Herein we investigate the cytotoxic potential of new small molecules against the Gram-positive bacterium *Paenibacillus larvae*, the causative agent of the American Foulbrood disease (AFB). Furthermore, we were interested to study the activity of these compounds against different cancer cell lines.




**Figure 1.** A) *Apis* species: (a) *Apis mellifera*, (b) *Apis cerana*, (c) *Apis dorsata*, (d) *Apis florae* [3]. B) Healthy Brood Cells (top) and Brood Cells Infected with Foulbrood (bottom). C) *Paenibacillus larvae*.

## Anti-bacterial and antitumor efficacy



**Figure 2:** Work-flow of the screening procedure.

Until now, we have investigated the anti-bacterial and antitumor efficacy of a series of novel, small molecule-based compounds and compared their biological effects with those of well-known reference drugs, including cis-Pt, carbo-Pt, etoposide, and doxorubicin (Fig. 2). All compounds were further tested for their cytotoxicity on various tumor cell lines, including HepG2, MDA-MB-231, HT-29, and the non-tumor 3T3. A two-step screening procedure was applied in order to identify highly selective compounds against the target pathogen *Paenibacillus larvae* in comparison with the standard antibiotic lincomycin (Fig. 2 and 3).




**Figure 3.** Anti-bacterial effects of Cmpd. PBDD1-8 (K-8) on eight bacterial types (A) and against *Paenibacillus larvae* (PL) in comparison with lincomycin (B).

## New insights into cytotoxicity

To further investigate the possible mechanism of action (MoA) of compound BPDD1-8 (K-8), for example apoptotic effects, we performed initial time- and concentration-dependent fluorescence spectroscopy (Axio fluorescent microscope) using HepG2 cancer cells (Fig. 4).

After 4 h incubation time, the cells were stained with the respective fluorescence dye (DAPI, 4',6-diamidino-2-phenylindole) which showed appearance of a cytotoxic effect compared with non-treated cells. This method allowed us to obtain the appropriate effective concentrations of BPDD1-8 in the subsequent apoptosis and cell cycle studies.



**Figure 5.** Representative photos of the fluorescent microscopy experiments with BPDD1-8 on HepG2 cell line. The cells were treated for 4h at 37°C at different compound's concentrations (1.0, 2.5, 5.0, and 50 µM).

## Conclusions

The biological effects of these new compounds are comparable to those of the approved antibiotic lincomycin and the anti-cancer drug doxorubicin. Based on their cytotoxic and antiproliferative activity two of the new drug candidates (designated as BPDD1-3 / NT-3 and BPDD1-8 / K-8) were chosen for further studies identifying their mechanisms of action, e.g., apoptosis and cell cycle on cancer cells.

**Acknowledgments:** The authors acknowledge the financial support by the Bulgarian National Science Found (BNSF) under Grant No. KP-06-N59/2.

## Literature

- [1] Ebeling, J. et al. *Appl. Microbiol. Biotechnol.* **2016**, 100(17), 7387–95.
- [2] Matović, K. et al. *Vet. Sci.* **2023**, 10(3), 180.
- [3] Makkar, G.S. et al. *Vegetos* **2020**, 33, 538–544.